Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 50 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues.
|Type||Public / Private|
Establishment & Growth 1961 Ranbaxy incorporated as a company 1973 Ranbaxy launches IPO 1983 Sun Pharma established with 5 psychiatry products and a two person marketing team 1985 Ranbaxy research foundation set-up 1994 Sun Pharma launches IPO 1996 Sun Pharma expands sales network across 24 countries 1997 Ranbaxy crosses sales turnover of INR 10,000 million,with export reaching an all-time high of INR 5,000 million 1998 Ranbaxy enters USA with products under own name 2001 Ranbaxy crosses sales of US $100 million in the US,becoming the fastest growing pharmaceutical company 2003 Ranbaxy enters into global alliance with GSK for drug discovery and development 2004 Ranbaxy joins the elite club of Billion Dollar Company SPARC In 2007, Sun Pharma demerged its innovative R&D arm, and listed it separately on the stock market as the Sun Pharma Advanced Research Company Ltd. (NSE: SPARC, BSE: 532872). In 2013, SPARC declared revenue of Rs. 873 million. SPARC focuses on new chemical entities (NCE) research and new drug delivery systems and offers an annual update of its pipeline (NDDS). Acquisitions and Joint Ventures Sun Pharma has complemented growth with select acquisitions over the last two decades. In 1996, Sun purchased a bulk drug manufacturing plant at Ahmednagar from Knoll Pharmaceuticals and MJ Pharma's dosage plant at Halol that are both U.S. FDA approved today. In 1997, Sun acquired Tamil Nadu Dadha Pharmaceuticals Limited (TDPL) based in Chennai, mainly for their extensive gynaecology and oncology brands. Also in 1997, Sun Pharma initiated their first foray into the lucrative US market with the acquisition of Caraco Pharmaceuticals, based in Detroit. Awards Sun Pharma stood second in the India's Most Reputed Brands (Pharmaceutical) list  in a study conducted by BlueBytes, a leading Media Analytics firm in association with TRA Research, a brand insights organization (both a part of the Comniscient Group).
India's largest drugmaker Sun Pharma gets warning letter from FDA  India’s largest drug maker Sun Pharmaceutical Industries Ltd on Tuesday said the US Food and Drug Administration (FDA) has decided to lift an import alert on its manufacturing plant at Mohali in Punjab.
The US FDA had imposed the import alert in 2013 for violation of good manufacturing practices.
“This proposed action (by US FDA) will clear the path for Sun Pharma to supply approved products from the Mohali facility to the US market, subject to normal US FDA regulatory requirements. It illustrates Sun Pharma’s commitment to work closely with the US FDA and strive for 100% cGMP (current good manufacturing practices) compliance at its manufacturing facilities, “ the company said in a stock exchange filing.
The Mohali plant came into the Sun Pharma fold when it acquired Ranbaxy Laboratories Ltd in 2015.
Shares of Sun Pharma jumped at the announcement, closing 3.4% higher at Rs707 on the BSE, while benchmark Sensex index closed up 1.6% at 29421.82 points.
The US drug regulator will also remove the facility from the status of Official Action Indicated (OAI), Sun Pharma said.
Top 5 Recent News Headlines
Sun Pharma buoyed by success of new products 
July 4, 2017 (Reuters) - Sun Pharmaceutical Industries Ltd :
* Strategic manufacturing tie-up with Samsung Biologics for Tildrakizumab
* Unit, Samsung Biologics to manufacture Tildrakizumab
* Drug is an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis
* Approximate value of the contract will be US$ 55.5 million